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BACKGROUND: Fecal occult blood testing (FOBT) is an
important option for colorectal cancer screening that
should be available in order to achieve high population
screening coverage. However, results from a national
survey of clinical practice in 1999–2000 indicated that
many primary care physicians used inadequate meth-
ods to implement FOBT screening and follow-up.
OBJECTIVE: To determine whether methods to screen
for fecal occult blood have improved, including the use
of newer more sensitive stool tests.
DESIGN: Cross-sectional national survey of primary
care physicians.
PARTICIPANTS: Participants consisted of 1,134 prima-
ry care physicians who reported ordering or performing
FOBT in the 2006–2007 National Survey of Primary
Care Physicians’ Recommendations and Practices for
Cancer Screening.
MAIN MEASURES: Self-reported data on details of
FOBT implementation and follow-up of positive results.
RESULTS: Most physicians report using standard
guaiac tests; higher sensitivity guaiac tests and immu-
nochemical tests were reported by only 22.0% and
8.9%, respectively. In-office testing, that is, testing of a
single specimen collected during a digital rectal exam-
ination in the office, is still widely used although
inappropriate for screening: 24.9% of physicians report
using only in-office tests and another 52.9% report
using both in-office and home tests. Recommendations
improved for follow-up after a positive test: fewer
physicians recommend repeating the FOBT (17.8%) or
using tests other than colonoscopy for the diagnostic
work-up (6.6%). Only 44.3% of physicians who use
home tests have reminder systems to ensure test
completion and return.
CONCLUSIONS: Many physicians continue to use
inappropriate methods to screen for fecal occult blood.
Intensified efforts to inform physicians of recommended
technique and promote the use of tracking systems are
needed.
KEY WORDS: colorectal cancer; cancer screening; primary care; quality
of care; fecal occult blood test.
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INTRODUCTION
For more than a decade, major national organizations have
strongly recommended routine screening for colorectal can-
cer, the second leading cause of cancer-related death in the
U.S.
1–10 Although screening rates have increased, they re-
main considerably lower than the rates for other recom-
mended cancer screening tests.
11
Until recently the most widely used of the recommended
screening options was fecal occult blood testing (FOBT), shown to
be effective in reducing colorectal cancer incidence and mortality
in randomized controlled trials.
12–15 However, its effectiveness in
general clinical practice depends on the degree to which health
professionals follow recommended testing guidelines. A national
survey of primary care physicians conducted in 1999–2000
revealed serious problems in the way many physicians in the
U.S. implementedFOBTin practice.
16Ratherthan relying on the
multiple-specimen home test that was evaluated in the trials,
74% of physicians reported performing in-office tests, that is,
testing of a single stool specimen collected in the office during
digitalrectalexamination. Thein-officetesthasbeenshowntobe
a very poor test that misses 95% of advanced neoplasia.
17 The
survey also showed that follow-up of positive FOBTs was often
inconsistent with recommended standards of practice. Nearly
30% of physicians recommended repeating FOBTafter a positive
result rather than referring the patient for colonoscopy. Sigmoid-
oscopy, rather than colonoscopy, was commonly recommended
to work up abnormal findings. Analysis of data from a contem-
poraneous survey of adults, the 2000 National Health Interview
Survey (NHIS), showed similar results. These observations led
one commentator to speculate that, after many years of FOBT
testing in the population, colorectal cancer mortality rates might
be considerably lower today if more physicians had followed
recommended testing and follow-up methods.
18
Since 2000, screening patterns have changed considerably,
with colonoscopy becoming the most commonly used colorectal
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833cancer screening test.
11,19,20 However, FOBT is still recom-
mended by most primary care physicians.
20 It is preferred by a
significant fraction of adults
21 and is the only test available to
those with insufficient insurance coverage or who live in areas
with limited high quality endoscopic services. Using data from
the National Survey of Primary Care Physicians' Recommenda-
tions and Practices for Cancer Screening, conducted in late 2006
and early 2007, we reported in a recent paper the tests that
physicians recommend for colorectal cancer screening and the
office systems they use to support screening. We found that 95%
of primary care physicians routinely recommend colonoscopy
and 80% routinely recommend FOBT for colorectal cancer
screening.
20 Indeed, FOBT needs to remain part of every
practice's menu of screening options if high population coverage
is to be achieved. Growing evidence that the newer FOBTs are
superior to the standard guaiac test used in the original
screening trials suggests that FOBT may be a more effective
screening option now than when screening guidelines were first
issued.
22,23
Have physicians’ methods for implementing FOBT improved?
Since 2000, more recent versions of national screening guide-
lines have explicitly recommended against in-office FOBT and
against repeating FOBT in response to an initial positive
finding.
5–7,9 Billing codes were changed to emphasize that only
home tests are appropriate for screening.
24
We report here an in-depth analysis of FOBT practices using
data from the 2006–2007 primary care physician survey to
assess whether there has been improvement in the methods
physicians use to implement FOBT and their beliefs about and
use of the newer fecal occult blood tests.
METHODS
TheNationalCancerInstitute(NCI)collaboratedwiththeCenters
for Disease Control and Prevention (CDC) and the Agency for
Healthcare Research and Quality (AHRQ) to survey a nationally
representative sample of primary care physicians between
September 2006 and May 2007. The American Medical Associa-
tion’s Physician Masterfile was used to form the sample, which
included family practitioners, general practitioners, general
internists and obstetrician-gynecologists. A systematic, stratified
random sample was selected with the four specialty types as the
sampling strata. Eligible respondents were non-federal, office-
based physicians 75 years of age or younger who had an active
license to practice medicine and whose major professional
activity was patient care. Additional details of the sampling and
survey methods have been described elsewhere.
20
Questions about physicians’ colorectal cancer screening
recommendations and practices were specific to asymptomatic,
average-risk patients and were similar to those used in the
1999–2000 survey. Physicians were asked about their percep-
tions of the effectiveness of guaiac and immunochemical FOBT
in reducing colorectal cancer mortality. They were also asked,
‘For the majority of your patients, by what means do you
conduct FOBT for screening purposes: complete a single FOBT
card in the office during a digital rectal exam, give or mail
patients FOBT kits to complete at home, both of the above, or do
not use FOBT in my practice.’ Physicians were then asked which
procedure or procedures they usually recommended to healthy,
average-risk patients as an initial follow-up test after positive
results on FOBT. Physicians who reported repeating the FOBT
were asked if they stop the workup if the second FOBT is
negative. The questionnaire underwent cognitive interviewing
and survey materials were pre-tested among a small, randomly-
selected sample of primary care physicians. The survey
questionnaire is available at: http://healthservices.cancer.
gov/surveys/screening_rp/.
We assessed follow-up of positive FOBT results in two steps,
as before.
16 Among the 1,134 physicians who ordered or
performed FOBT at least once per month, we first looked at
whether they recommended repeating the FOBT. We then
examined which tests were recommended for the diagnostic
work-up. At this second step, we did not include respondents
who only reported repeated FOBT (n=104), those who only
indicated that they referred patients to another physician for
follow-up of positive FOBT results (n=28) and those whose
response we could not classify (n=3).
For the bivariate analyses of data, we performed a log-
likelihood chi-square test for the association between each of
the various physician or physicians' practice characteristics and
the outcome variables, i.e., percentage of physicians who use in-
office tests (Table 2) and percentage of physicians who repeat
FOBT after abnormal results (Table 3). For the multivariate
analyses, we performed logistic regression using the Wald chi-
square test to test the association between each physician or
practice characteristic and each of the outcomes described
above while controlling for all other variables in the respective
table. We computed predictive margins (adjusted percentages), a
type of direct standardization that averages the predicted values
from the logistic regression models over the covariate distribu-
tion in the population, allowing comparisons across categories
of the variables included in the models.
25 To permit generaliza-
tion of the results of all analyses to the U.S. population of
practicing primary care physicians, we used sampling weights
that account for the probability of selection and non-response.
WeusedtheSASstatisticalpackage,version9.1.3(SASInstitute,
Inc., Cary, North Carolina)
26, and SUDAAN, version 9 (Research
Triangle Institute, Research Triangle Park, North Carolina)
27 to
compute estimates, confidence intervals and P values.
This study was determined to be exempt from review by the
institutional review boards at the NCI and CDC.
RESULTS
Description of Respondents
A total of 1266 physicians responded to the survey. The
absolute response rate was 69.3%. The cooperation rate,
which measures participation among contacted physicians,
was 75.0%. Ninety percent of respondents (n=1134) indicated
that they ordered or performed FOBT as a colorectal cancer
screening method for asymptomatic average-risk patients at
least once during a typical month. The results reported below
are based on these 1134 physicians, whose personal and
practice characteristics are shown by specialty (Table 1).
Guaiac-Based and Immunochemical FOBT:
Perceived Effectiveness and Use
A total of 85.4% of physicians believed that guaiac-based tests
were somewhat or very effective in reducing colorectal cancer
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chemical tests were effective; 38.4% reported not knowing
about the effectiveness of the immunochemical tests (Fig. 1).
Use of standard guaiac-based cards, such as Hemoccult II
(Beckman Coulter, Fullerton, California), was reported by
61.1% (95% CI, 57.8%–64.3%) of physicians. Higher-sensitivity
FOBTs, such as Hemoccult SENSA (Beckman Coulter, Full-
erton, California), were used by 22.0% (CI, 19.8%–24.5%). Fecal
immunochemical tests were used by 8.9% (CI, 7.3%–10.9%). A
total of 14.7% (CI, 12.5%–17.2%) of physicians did not know the
brand of test they used.
Method of Conducting FOBT
Of the physicians who reported ordering or performing FOBT
for screening at least once per month, 22.2% (95% CI, 19.7%–
24.9%) used home-based FOBT exclusively for the majority of
their patients, 24.9% (CI, 22.3%–27.6%) used in-office FOBT
exclusively, and 52.9% (CI, 49.8%–56.1%) used both home and
in-office tests. Obstetrician-gynecologists were most likely to
use in-office tests exclusively (Fig. 2). Table 2 shows the
relationship between various physician characteristics and
use of in-office tests, either exclusively or in addition to home
tests. Physicians working in solo practices were more likely to
use in-office tests than physicians working in practices with
other physicians. Physicians who graduated from medical
school longer ago were more likely to use in-office tests than
those who graduated more recently, although the difference
was not statistically significant after adjustment for the key
demographic and practice variables listed. There was little
variation by physician gender, urban vs. rural practice loca-
tion, or affiliation with a medical school (data not shown).











%% % % %
Physician Characteristics
Gender (male) 69.1 88.5 61.9 68.6 68.4
Age (years)
<40 22.7 0.0 17.5 20.0 20.0
40–49 30.0 10.0 28.8 33.2 30.3
50–59 34.6 32.6 32.4 29.7 32.4
≥60 12.7 57.4 21.4 17.1 17.4
Race/ethnicity
Non-Hispanic White 78.5 75.5 74.1 64.7 72.6
Non-Hispanic Black 2.8 0.0 5.4 4.4 3.7
Hispanic 4.2 8.4 6.0 6.2 5.4
Non-Hispanic Asian 10.0 14.6 11.7 20.5 14.3
Other
b 4.6 1.5 2.8 4.2 4.0
Board certified (yes) 85.7 3.0 84.0 78.9 79.9
Medical school affiliation (yes) 34.2 17.5 43.7 33.7 35.0
Practice Characteristics
Metropolitan location
Urban 73.9 65.2 88.3 87.9 81.1
Large rural city/town 12.2 19.8 9.1 8.5 10.6
Small rural city/town 13.9 15.0 2.6 3.6 8.3
Practice type
Single specialty 75.7 80.3 75.8 66.7 72.6
Multi-specialty 19.7 11.6 21.2 30.9 23.8
Other/missing 4.6 8.1 2.9 2.4 3.7
Number of physicians in Primary location
1 24.7 54.5 23.1 26.5 26.2
2–5 47.4 28.4 34.0 39.7 42.1
6–15 19.6 13.9 26.5 20.9 21.0
≥16 8.3 3.2 13.5 12.9 10.7
aPercentages are weighted to account for the survey design. Percentages may not add to 100% because of rounding
bOther includes American Indian/Alaska Native, Native Hawaiian/Other Pacific Islander, multiple races, other race and unknown or missing.
Variables with missing data (<10 records): medical school affiliation, number of physicians in primary location
Figure 1. Perceived effectiveness of guaiac-based FOBT* and
immunochemical FOBT*. *FOBT = fecal occult blood test. Note:
Vertical lines within bars indicate 95% confidence intervals around
percentages.
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Repeating the FOBT. Overall, 17.8% of physicians recom-
mended repeating the FOBT as the initial follow-up step to a
positive FOBT (Table 3). Of the physicians who repeated
FOBT, 28.8% (95% CI, 22.9%–35.4%) reported stopping the
work-up when the second FOBT was negative and 71.2% (CI,
64.6%–77.1%) reported not stopping the work-up (data not
shown).
Physicians who graduated from medical school before 1978
were more likely to recommend repeating the FOBT than
physicians who graduated more recently. Physicians in solo
practice were more likely to repeat the FOBT than physicians in
larger practices, although the difference was not statistically
significant after adjustment for the other physician character-
istics listed. In contrast to physicians who exclusively used
home tests, those who used only in-office tests were more than
twice as likely to repeat the FOBT. Physicians who were not
board-certified were more likely to repeat the test.
Diagnostic Work-Up. Among the 999 physicians who reported
follow-up tests other than repeated FOBT, colonoscopy alone
was recommended by 93.4% (95% CI, 91.9%–94.6%). A total of
4.6% (CI, 3.5%–6.0%) of physicians recommended sigmoido-
scopy alone or sigmoidoscopy and/or colonoscopy. Physicians
who were not board-certified were the most likely to recommend
follow-up other than colonoscopy alone (16.5%; CI, 11.8%–22.-
6%) (data not shown).
Use of Reminder Systems
When asked if they had a mechanism to ensure that patients
completed and returned home tests, 44.3% (95% CI, 41.0%–
47.6%) of physicians who used home tests responded affirma-
tively. Chart reminders or other office systems were reported
by 29.7% (CI, 26.6%–33.1%), telephone reminders by 13.3%
(CI, 11.3%–15.5%) and mail reminders by 7.2% (CI, 5.5%–
9.3%).
When asked if they had a mechanism “to ensure that
patients with positive FOBT results complete initial follow-up
testing,” 62.2% (95% CI, 58.9%–65.3%) responded affirmative-
ly. It was not possible to tell what proportion of these
physicians actually follow their patients to diagnostic test
completion as opposed to merely informing them of their
positive screening result or scheduling the diagnostic test.
Reminder telephone calls were reported by 35.9% (CI, 33.1%–
38.7%), mailed reminders by 11.5% (CI, 9.8%–13.6%), tracking
systems or other office systems by 18.5% (CI, 16.4%–20.9%)
and scheduling systems by 15.3% (CI, 13.0%–17.8%).
Table 2. Percentage of Physicians Who Use In-office Fecal Occult Blood Tests
a
Variable Physicians, n
b Percentages (95% CI) P Value
c Adjusted percentages (95% CI)
d P Value
e
All 1134 77.8 (75.1–80.3)
Specialty 0.006 0.002
Family practice 452 73.6 (68.8–77.9) 74.2 (69.5–78.5)
General practice 61 85.1 (74.6–91.7) 75.0 (58.6–86.4)
Obstetrics-gynecology 249 84.4 (80.4–87.6) 84.8 (81.0–87.9)
Internal medicine 372 79.1 (73.9–83.6) 79.2 (74.0–83.6)
Year of medical school graduation 0.009 0.13
1955–1977 285 83.9 (78.6–88.0) 81.9 (76.1–86.6)
1978–1985 282 79.6 (73.3–84.7) 78.9 (72.6–84.2)
1986–1994 282 77.7 (72.4–82.2) 78.7 (73.8–82.9)
1995–2002 285 70.5 (64.1–76.2) 72.9 (66.8–78.3)
Number of physicians in practice <0.001 <0.001
1 292 87.9 (84.0–90.9) 87.1 (83.0–90.3)
2–5 472 78.5 (74.4–82.2) 79.2 (75.1–82.8)
6+ 363 68.7 (63.8–73.2) 68.8 (63.8–73.4)
Board Certified 0.05 0.20
Yes 891 76.5 (73.3–79.5) 77.0 (73.8–79.9)
No 243 82.9 (77.3–87.3) 81.7 (75.0–86.9)
aData are percentages of physicians who reported using in-office tests only or both in-office and home tests, weighted to account for the survey design
bThese numbers are the denominators for the percentages
cBased on a log-likelihood Chi-square test for association
dBased on 1127 physicians in the analysis. Percentages are adjusted for all other variables in the table using predictive margins from a logistic regression
model
eBased on a global Wald chi-square test for association using a logistic regression model
Figure 2. Method of conducting FOBT* for screening, by physician
specialty. *FOBT = fecal occult blood test; FP = family physician;
GP = general practitioner; OB/GYN = obstetrician gynecologist;
IM = internist. Note: Vertical lines within bars indicate 95%
confidence intervals around percentages.
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Colorectal cancer screening patterns have changed dramati-
cally since 2000, with most primary care physicians now
recommending both FOBT and colonoscopy to their average-
risk patients.
20 However, the current study shows that, as in
2000, three-quarters of primary care physicians who recom-
mend FOBT use in-office tests. While FOBT done appropriately
is an important screening option, in-office FOBT may be worse
than no screening at all because it misses 95% of cases of
advanced neoplasia, giving many patients a false sense of
reassurance.
17,18
At the time of the 2000 survey, it had not been possible to
distinguish in-office from home tests by Current Procedural
Terminology (CPT) coding. In response to our earlier findings,
CDC joined with the American Cancer Society (ACS) and
other organizations to recommend changing the coding for
FOBT so that the two types of test could be distinguished.
The revised CPT code, which specifies that the patient was
provided three single cards or single triple card for consecu-
tive collection, was introduced in January 2006.
24 Since
January 2007, the Medicare program reimburses for colorec-
tal cancer screening with FOBT only when this new code is
used.
28
Despite published evidence of low accuracy, and the change
in CPT codes to reinforce appropriate use of FOBT, our
survey results provide no evidence of a shift away from the
use of in-office tests. Changes in longstanding practice and
accurate use of new codes may require more time than has
elapsed between the coding changes and our survey. Physi-
cians may use the in-office test because they are frustrated
with poor patient compliance with home tests and feel that
in-office testing is better than no screening at all. Instead,
they should direct more effort toward encouraging patients
to complete the home test.
18 Both patient and provider
reminder systems have been shown to be effective in
increasing adherence
29,30 but were reported by only a
minority of physicians in our survey. Frequent use of in-
office tests by obstetrician-gynecologists probably reflects the
fact that they routinely perform digital rectal examinations
as part of the pelvic examination and thus the in-office test
is easily accomplished. Since late 2006, the American
College of Obstetricians and Gynecologists specifically
recommends against the use of in-office tests for colorectal
cancer screening.
31
As in 2000, most physicians in the current survey reported
using standard guaiac-based tests, such as those used in the
randomized trials, rather than the newer guaiac tests or fecal
immunochemical tests. These newer tests generally have
been shown to have higher sensitivity for colorectal cancer
and advanced lesions than the standard guaiac test, although
the specificity of the high-sensitivity guaiac test appears to be
lower than that of standard guaiac and at least some of the
immunochemical tests.
32 The recent guideline developed
jointly by the ACS, the Multi-Society Task Force on Colorectal
Cancer, and the American College of Radiology explicitly
recommends that screening should be limited to tests that
have single-application sensitivity for cancer >50%, thus
excluding standard guaiac tests as an acceptable option.
9
The decision analysis recently performed for the U.S. Preven-
Table 3. Percentage of Physicians Who Repeat Fecal Occult Blood Tests after Abnormal Results
a
Variable Physicians, n






All 1131 17.8 (15.8–19.9)
Specialty <0.001 0.67
Family practice 451 16.5 (13.3–20.2) 18.2 (14.8–22.1)
General practice 61 40.0 (28.5–52.8) 23.0 (14.1–35.3)
Obstetrics-gynecology 247 19.3 (14.8–24.9) 17.3 (13.1–22.6)
Internal medicine 372 16.4 (12.8–20.7) 16.7 (13.2–21.0)
Year of medical school graduation <0.001 <0.001
1955–1977 284 28.5 (24.0–33.5) 25.2 (21.0–29.9)
1978–1985 282 16.5 (11.9–22.3) 16.3 (11.8–22.0)
1986–1994 281 10.8 ( 7.7–15.1) 11.6 ( 8.2–16.1)
1995–2002 284 15.7 (11.7–20.8) 17.5 (12.8–23.4)
Number of physicians in practice <0.001 0.13
1 291 26.0 (20.6–32.1) 22.0 (17.0–28.1)
2–5 472 15.5 (12.7–18.8) 16.1 (13.2–19.5)
6+ 361 14.0 (11.1–17.4) 15.8 (12.6–19.6)
Type of FOBT <0.001 0.002
Office only 295 24.1 (19.6–29.4) 24.0 (19.4–29.3)
Home only 243 10.0 ( 6.6–14.7) 10.7 ( 6.9–16.1)
Both 593 18.0 (15.5–20.9) 17.5 (14.9–20.4)
Board Certified <0.001 0.004
Yes 888 14.8 (12.7–17.3) 15.7 (13.3–18.3)
No 243 29.3 (23.7–35.8) 25.1 (19.5–31.7)
aData are percentages of physicians who recommended repeating the FOBTafter positive FOBT result, weighted to account for the survey design. FOBT =
fecal occult blood test
bThese numbers are the denominators for the percentages
cBased on a log-likelihood Chi-square test for association
dBased on 1124 physicians in the analysis. Percentages are adjusted for all other variables in the table using predictive margins from a logistic regression
model
eBased on a global Wald chi-square test for association using a logistic regression model
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years gained will be greater with screening strategies that use
either the extra-sensitive guaiac or the immunochemical tests
than with the standard guaiac test
23 and the 2008 recom-
mendation from the U.S. Preventive Services Task Force
specifies screening with high-sensitivity FOBT.
8
In addition to offering higher sensitivity, the immunochem-
ical tests may be more acceptable to patients because they do
not require dietary restriction and the sample collection
methods for some of the tests are designed to be more user-
friendly, requiring fewer samples or less direct handling of
stool.
33,34 Medicare began covering immunochemical tests in
2004, making them a viable option. In our study, almost 40% of
physicians reported not knowing about the effectiveness of the
immunochemical tests. Although more research is needed to
clarify the comparative performance characteristics of the
various FOBTs, education is needed to increase physician
awareness of available information about the performance of
the newer stool tests.
One area of some improvement identified by this study is
that fewer physicians are recommending repeating the FOBT
following a positive initial test. In the earlier survey, nearly 30%
of physicians recommended repeating the FOBT as the initial
follow-up step to a positive FOBT, rather than immediately
recommending total colon examination as suggested in na-
tional guidelines.
16 We could not tell in the earlier survey if
some of these physicians recommended diagnostic work-up
even if the second sampling yielded negative results. In the
current survey, 17.8% of physicians recommended repeating
the test and, of these, only 28.8% reported stopping the work-
up if the second test is negative. It is not clear why some
physicians repeat the FOBT after a positive test if they
continue with the diagnostic work-up regardless of the result
of the second FOBT.
The current survey also shows that most physicians now
recommend colonoscopy for the diagnostic work-up, a marked
improvement since the earlier survey, when almost one-third
recommended sigmoidoscopy, which can miss many polyps
and cases of cancer.
16 This change likely reflects the recent
shift from sigmoidoscopy to colonoscopy.
11,20,35,36
Studies of patients with positive FOBTs have documented
that many such patients do not receive any follow-up of their
positive test.
16,37,38 A common reason found for lack of follow-
up is that the patient had undergone colonoscopy within the
previous few years.
37,38 Indeed, the use of FOBT within 5 years
of a negative colonoscopy is discouraged
39,40 because of the
low yield of significant lesions after recent screening colono-
scopy in average-risk patients. However, a recent survey of
gastroenterologists in New Haven County, Connecticut found
that the majority recommend annual FOBT beginning 1 to
5 years after a normal screening colonoscopy.
41 In our survey,
for physicians who recommended more than one test modality,
the precise patterns of use of the multiple modalities are
unknown. It may be that some of the physicians who
recommend both FOBT and colonoscopy for screening may
order or perform FOBT during the interval between colonos-
copies. Physician education is needed on the appropriate
indications for FOBT, since interim FOBT after a normal
colonoscopy is not supported by the evidence and not en-
dorsed by any organizational guidelines.
A limitation of this study is that the survey relies on self-
reports and has not been validated. To the extent that
physicians overreport correct behavior, our results may under-
estimate the proportions of physicians who recommend inap-
propriate practices.
CONCLUSION
Although FOBT is an important option for colorectal cancer
screening, our study suggests that its potential to save lives is
not currently being realized because many physicians are
continuing to use inappropriate implementation methods.
Intensified efforts to inform physicians of recommended tech-
n i q u ea n dp r o m o t et h eu s eo fs y s t e m sf o rt r a c k i n gt e s t
completion and follow-up are needed.
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